TC BioPharm Has Been Granted European Patent Number EP3283620 Titled "Modified Gamma Delta Cells And Uses Thereof (For The Treatment Of Cancer Or Infectious Diseases)".
Portfolio Pulse from Benzinga Newsdesk
TC BioPharm has been granted European Patent Number EP3283620 for 'Modified Gamma Delta Cells And Uses Thereof' aimed at treating cancer and infectious diseases.
July 29, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TC BioPharm has been granted a European patent for 'Modified Gamma Delta Cells And Uses Thereof' which could enhance its product offerings in cancer and infectious disease treatments.
The granting of this patent could significantly enhance TC BioPharm's product portfolio and market position in the biotech sector, particularly in cancer and infectious disease treatments. This is likely to positively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100